These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
302 related items for PubMed ID: 23082215
1. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Wang X, Li YM, Li WQ, Huang CG, Lu YC, Hou LJ. PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215 [Abstract] [Full Text] [Related]
4. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients. Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T. Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833 [Abstract] [Full Text] [Related]
7. The effectiveness and safety of clazosentan in treating aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. Al-Salihi MM, Saha R, Abd Elazim A, Helal A, Sabah Al-Jebur M, Al-Salihi Y, Ayyad A. J Clin Neurosci; 2024 Aug; 126():173-181. PubMed ID: 38924824 [Abstract] [Full Text] [Related]
9. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series. Barth M, Capelle HH, Münch E, Thomé C, Fiedler F, Schmiedek P, Vajkoczy P. Acta Neurochir (Wien); 2007 Aug; 149(9):911-8; discussion 918. PubMed ID: 17700991 [Abstract] [Full Text] [Related]
10. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage. Mayer SA, Aldrich EF, Bruder N, Hmissi A, Macdonald RL, Viarasilpa T, Marr A, Roux S, Higashida RT. Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993 [Abstract] [Full Text] [Related]
16. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study. Higashida RT, Bruder N, Gupta R, Guzman R, Hmissi A, Marr A, Mayer SA, Roux S, Weidauer S, Aldrich EF. World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336 [Abstract] [Full Text] [Related]
17. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Frey A, Marr A, Roux S, Kassell NF. Neurocrit Care; 2010 Dec; 13(3):416-24. PubMed ID: 20838933 [Abstract] [Full Text] [Related]
18. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. Endo H, Hagihara Y, Kimura N, Takizawa K, Niizuma K, Togo O, Tominaga T. J Neurosurg; 2022 Dec 01; 137(6):1707-1717. PubMed ID: 35364589 [Abstract] [Full Text] [Related]
20. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Shen J, Huang KY, Zhu Y, Pan JW, Jiang H, Weng YX, Zhan RY. J Neurosurg; 2017 Aug 01; 127(2):291-301. PubMed ID: 27715439 [Abstract] [Full Text] [Related] Page: [Next] [New Search]